Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04924140 · ClinicalTrials.gov registry record · Phase 1
A Study to Assess Absolute Bioavailability of Aducanumab in Healthy Volunteers
A Phase 1 study, sponsored by Biogen.
- Completed
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
NCT04924140 is a Phase 1 study that has completed, run by Biogen. The registered enrollment target is 30 participants.
The verdict
NCT04924140, a Phase 1 study, has completed, sponsored by Biogen.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
Study Summary
The primary objective of this study is to evaluate the absolute bioavailability of a single, fixed subcutaneous (SC) dose of aducanumab compared with a single weight-based intravenous (IV) dose of aducanumab in healthy volunteers. The secondary objectives of this study are to assess the safety and tolerability of aducanumab administered SC in healthy volunteers and to characterize additional pharmacokinetic (PK) parameters of a single, fixed SC dose of aducanumab and a weight-based IV dose of aducanumab in healthy volunteers.
Interventions
- DRUG Aducanumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2021-06-30 |
| Est. Completion | 2021-10-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04924140
The ClinicalTrials.gov registry entry for NCT04924140 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Biogen, which has 334 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Aducanumab is the first listed.
NCT04924140 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04924140 about?
NCT04924140 is a clinical study titled "A Study to Assess Absolute Bioavailability of Aducanumab in Healthy Volunteers". The primary objective of this study is to evaluate the absolute bioavailability of a single, fixed subcutaneous (SC) dose of aducanumab compared with a single weight-based intravenous (IV) dose of aducanumab in healthy volunteers. The secondary objectives of this study are to assess the safety and ...
What is the current status of trial NCT04924140?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2021-06-30. Estimated completion is 2021-10-01.
What interventions are being tested in trial NCT04924140?
The interventions under investigation include: Aducanumab (DRUG).
Who is sponsoring clinical trial NCT04924140?
This trial is sponsored by Biogen, which has 334 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.